LGND Ligand Pharmaceuticals Incorporated

101.97
+2.7  (+3%)
Previous Close 99.27
Open 102.81
Price To Book 1.86
Market Cap 1,938,600,004
Shares 19,011,474
Volume 313,631
Short Ratio
Av. Daily Volume 436,912

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
Data due by the end of 3Q 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 top-line data due 1H 2021.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2b trial to be initiated 2H 2019.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 data due no later than early 1Q 2020.
SB206
Molluscum contagiosum skin infection
PDUFA date under priority review - October 24, 2019.
Baxdela
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
Phase 1 preliminary data due 4Q 2019.
APVO436
Acute myeloid leukemia (AML)
Phase 2 data met primary endpoint - August 5, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 1 top-line data met primary endpoint - July 10, 2019.
Captisol-enabled (CE) Iohexol program
Contrast-induced Nephropathy
Phase 2b data due 4Q 2019 or 1Q 2020.
Ensifentrine (RPL554) and tiotropium
Chronic obstructive pulmonary disease (COPD)
Phase 2 data from first part of trial due 2H 2019. Final data 1Q 2020.
Ensifentrine (RPL554) - Metered Dose Inhaler
Maintenance treatment of COPD
Phase 3 trial has been initiated by partner CStone Pharmaceuticals.
CS1001
Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.